Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of ...

Aptevo Therapeutics (NASDAQ:APVO) announced two additional frontline Acute Myeloid Leukemia (AML) patients have achieved ...

Contemplated merger with Decoy Therapeutics progressing as planned; upon closing, combined company expected to accelerate clinical development of novel peptide conjugate therapeutics for treating resp ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care Triplet Combination with mipletamig continues to outperform ...

Aptevo Therapeutics (APVO) announced two additional frontline AML patients have achieved remission within 30 days of treatment in the Company’s ...

Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of careTriplet Combination with mipletamig continues to outperform do ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics , a leader in the ...

A phase 3 study is ongoing to confirm the survival benefit of venetoclax plus azacitidine in patients with treatment-naive high-risk MDS. The combination of venetoclax plus azacitidine was well ...

Cytogenetic analysis of bone marrow aspirate demonstrated myelodysplastic syndrome (MDS). Systemic chemotherapy with azacitidine was then initiated, achieving haematological stability and quiescence ...

Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...

After hours: March 20 at 6:52:54 p.m. EDT Loading Chart for SLRX ...